FTC Finalizes Amendments To HSR Rules Regarding Transfer Of Exclusive Patent Rights In The Pharmaceutical Industry

by Pepper Hamilton LLP
Contact

The Federal Trade Commission (FTC) has finalized certain amendments to the Hart-Scott-Rodino (HSR) premerger notification regulations clarifying the scope of reportable transactions involving transfers of patent rights in the pharmaceutical industry.1 The final version of the rule is identical to that originally proposed in August 2012.

The Background

Generally, HSR filings are required for certain size acquisitions of voting securities, assets, or controlling shares of non-corporate interests. The FTC has always treated patents as assets, requiring HSR filings for acquisitions of patents valued in excess of the applicable jurisdictional thresholds. Traditionally, exclusive licenses of patents, in their entirety or for a particular field of use, indication, or geography, also have been treated as asset acquisitions. More recently, certain complexities in licenses related to pharmaceuticals, including (1) licensors retaining the right to co-develop, co-promote, co-market, or co-commercialize the product along with the licensee and (2) the licensor retaining the right to manufacture for exclusive sale to the licensee, have raised concern at the FTC.

The amendment addresses when a patent license will be treated as exclusive and, therefore, a reportable transfer of an asset. Historically, whether a transfer of rights to a patent was deemed an asset acquisition turned on whether the license granted the licensee the exclusive right to “make, use and sell.” Under the old rule, if a licensor retained the right to manufacture under the patent, but granted the rights to use and sell, the transaction was nonreportable. The FTC viewed such a limited transfer as, essentially, a distribution agreement rather than an asset sale.

The Amended Rule

Under the amended rule, whether a license transfers all rights to “make, use and sell” is no longer determinative. Instead, the applicable test will be whether a pharmaceutical patent license transfers “all commercially significant rights.” The principle change in reportability is that an HSR filing will be required for exclusive licenses, where the licensee retains the right to manufacture solely for the licensee, if the applicable size-of-person and size-of-transaction tests are satisfied.

The FTC has concluded that the right to manufacture, under a pharmaceutical and biological patent, is far less competitively significant than the right to commercialize. Pharmaceutical companies often enter into licenses in which the licensee receives the exclusive right to use and sell under the license, but the licensor retains the right to manufacture exclusively for the licensee. Because the licensor is manufacturing solely for the use of the licensee, the FTC has determined that such transfers are substantively the same as granting the licensee the exclusive right to manufacture, use and sell the products.

Under the amended rule, commercially significant rights are defined as the exclusive patent rights to use the patent in a particular therapeutic area or in a specific indication within a therapeutic area. The “all commercially significant rights” test focuses on whether the licensee receives the exclusive rights to commercially use the patent and receive the right to generate revenues from those exclusive patent rights, even if some of those profits will be shared with the licensor through royalties or other revenue-sharing terms.

Importantly, with the exception of the treatment of the right to manufacture exclusively for the licensee, the amended rule treats the reportability of exclusive license agreements, including those where the licensor retains “co-rights,” in the same way as the FTC has in the past. Exclusive patent transfers over a certain size remain reportable even when the licensor retains certain co-rights to co-develop, co-promote, co-market, or co-commercialize the exclusively licensed patent.

The FTC noted that when the licensor retains co-rights, typically only the licensee can use the patent rights as it works to gain FDA approval for the pharmaceutical product, and any royalty stream or other revenue-sharing mechanism flows from this exclusivity. Even though the licensee and licensor will share the eventual profits, the profits result from a reportable transfer to the licensee of the exclusive right to use the patent. This approach will not change under the proposed “all commercially significant rights” concept. Whether a license constitutes an asset transfer does not turn on the type, magnitude or scope of the co-right retained, but on whether the exclusive patent license allows only the licensee to commercially use the patent or part of the patent.

Many Exclusive Licenses will Remain Not Reportable

Even where the license is treated as an asset acquisition, often early-stage pharmaceutical collaborative licensing arrangements do not meet the HSR jurisdictional thresholds. An exclusive patent license will only be reportable if the $14.2 million (adjusted annually) size-of-person and the $70.9 million (adjusted annually) size-of-transaction thresholds established by the HSR Act are satisfied. Many times one of the parties to the license is a smaller firm that does not meet the size-of-person test (often times the licensor is a small company with limited assets and no sales) and the fair market value of the license at issue does not exceed the above size-of-transaction test. The HSR rules regarding valuation of the payments contemplated by such licenses often result in exclusive license values under the size-of-transaction threshold.2 For example, because of the substantial uncertainty of reaching later-stage milestones triggered by achieving new phases in clinical trials and new drug applications, in some cases such milestones can be discounted to zero.

The purpose of the amendment is to permit the FTC and the U.S Department of Justice an opportunity to review licenses, before they have been entered into, that they believe could have the same competitive effect that a straightforward transfer of the patent would have. Even though the treatment of licenses where licensees retain co-rights will not change, as a result of the new rule, parties entering into exclusive licenses whereby the licensor retains the right to manufacture the patented product for sale exclusively to the licensee will need to consider carefully whether their licensing arrangement triggers an HSR filing and how the complex pharmaceutical licensing valuation principles apply.

Endnotes

1 The amended rule applies to pharmaceutical licenses only. The FTC will consider all other exclusive licenses, including those for medical devices, on a case-by-case basis.

2 Of course, even transactions that fall below the HSR jurisdictional tests are subject to review by the FTC or Department of Justice (DOJ), Antitrust Division. See, e.g., FTC v. Solera / Actual Systems (FTC enters into consent decree related to $8.7 million acquisition); United States v. Bazaarvoice / PowerReviews (DOJ sues to unwind non-reportable transaction).

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pepper Hamilton LLP | Attorney Advertising

Written by:

Pepper Hamilton LLP
Contact
more
less

Pepper Hamilton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!